Semaglutide Dose Schedule (Ozempic, Wegovy)

Ozempic injection: an initiation stage and conditional increases

Ozempic injection starts at 0.25 mg weekly for four weeks and then reaches 0.5 mg weekly. A later increase to 1 mg requires at least four weeks at 0.5 mg when additional glycemic control is needed; an increase to 2 mg requires at least four weeks at 1 mg. The current label also specifies 1 mg after at least four weeks at 0.5 mg for its kidney-outcome indication. Ozempic label

Read phases with the table below. Bar height does not represent dose size.

Ozempic injection: section 2.2 Ozempic label
Interval	Weekly amount	Condition
1–4	0.25 mg weekly	Initiation
5 onward	0.5 mg weekly	After four weeks at 0.25 mg
After ≥4 weeks at 0.5 mg	1 mg weekly	If more glycemic control is needed; also the labeled kidney-outcome dose
After ≥4 weeks at 1 mg	2 mg weekly	If more glycemic control is needed; maximum weekly dose

Wegovy injection: indication-specific maintenance

Wegovy injection uses four-week stages of 0.25, 0.5, 1, and 1.7 mg weekly before maintenance. For adult weight management, the ongoing amount is 1.7 or 2.4 mg weekly. The current label permits 7.2 mg for adults who tolerate 2.4 mg for at least four weeks when additional weight reduction is clinically indicated. That conditional option does not apply to every Wegovy indication or age group. Wegovy label

The label can also delay escalation when a stage is not tolerated. Thus, the numbered weeks summarize the reference sequence, not a promise about the calendar of an individual person. A record that remains at one strength longer than the table illustrates is not enough information to judge the prescription. The table is a way to read the label, not a substitute for it. Wegovy label

Wegovy injection: adult weight-management reference, section 2.2 Wegovy label
Interval	Weekly amount	Condition
1–4	0.25 mg weekly	Initiation
5–8	0.5 mg weekly	Escalation
9–12	1 mg weekly	Escalation
13–16	1.7 mg weekly	Escalation
17 onward	1.7 or 2.4 mg weekly	Adult weight-management maintenance
After ≥4 weeks at 2.4 mg	7.2 mg weekly, if prescribed	Adult weight reduction only: tolerability and clinical need conditions apply

Oral semaglutide belongs in a separate table

Rybelsus uses 3 mg daily for thirty days, then 7 mg daily for the next thirty days, followed by 7 or 14 mg according to glycemic need. Ozempic tablets use different labeled strengths: 1.5, 4, and 9 mg. The combined tablet label says those two tablet products are not substitutable milligram for milligram. Copying an injection amount into either tablet schedule loses essential product information. Rybelsus label

Wegovy tablets have their own sequence of 1.5, 4, and 9 mg daily in successive thirty-day stages, followed by 25 mg daily. The injection and tablet label includes switching instructions, which are not a general arithmetic ratio between routes. The daily oral amount and the weekly injected amount describe different labeled uses, even though both names include semaglutide. Wegovy label

Use the tracker to preserve dates and context

PinPoint includes reminders, titration phases, and a color-coded calendar. Injection logs capture compound, amount, site, and pain level, with backfilling for earlier entries. A meaningful history keeps the dose associated with its actual recorded date. Daily notes and side-effect severity ratings can preserve observations without turning timing alone into a causal conclusion. App features

For vial arithmetic only, 5 mg in a final volume of 2 mL equals 2.5 mg/mL; 0.20 mL then contains 0.5 mg. A U-100 scale labels that volume as 20 units. The semaglutide calculator can reproduce this input-based result, but it cannot select the label schedule, identify a mystery concentration, or equate a compounded solution with an approved pen or tablet. Arithmetic

Useful distinctions

Questions

Is there one semaglutide dosage chart for every product?

No. The labels contain distinct injection and oral schedules, with indication-specific conditions. A useful reference identifies the brand presentation and route before displaying the amount. Ozempic label Wegovy label Rybelsus label

Can PinPoint show a changing prescribed phase?

The app description includes step-up and step-down titration phases and reminders that follow the entered schedule. It does not describe the app as selecting a clinical dose. App features

Your record, together

Keep the details attached to the date.

Dose history, reminders, daily notes, and the context you choose to record. PinPoint app features.

Get PinPoint on the App Store

Sources & scope

Label facts link to the full prescribing information. Product claims use the supplied PinPoint app description. Numerical examples show their assumptions and arithmetic.

PinPoint feature description
Only feature claims verified against the supplied description. No prices, clinical recommendations or inferred tablet inventory.
Arithmetic shown on this page
Numerical derivations, dimensional distinctions and declared assumptions only.
Concentration mg/mL = total mg / final mL. U-100 volume mL = units / 100. Contained mg = concentration * volume. These are hypothetical examples, not preparation instructions or clinical amounts.
How to read this reference
Editorial organization, explicit scope limits, and interpretation of the cited label or app evidence. No additional medical facts.
Ozempic prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: adec4fd2-6858-4c99-91d4-531f5f2a2d79.
Rybelsus prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: 27f15fac-7d98-4114-a2ec-92494a91da98.
Wegovy prescribing information
2 (schedule/administration), 3 (presentations), 6.1–6.2 (adverse reactions), 14 (study identity), Medication Guide and Instructions for Use. DailyMed set ID: ee06186f-2aa3-4990-a760-757579d8f77b.